All Evaluable Patients Achieved Improvements in Multiple Hallmarks of MYBPC3-Associated HCM Benefits Among Cohort 1 Patients ...
Bristol Myers Squibb (NYSE: BMY) today announced the U.S. Food and Drug Administration (FDA) accepted a supplemental New Drug Application (sNDA) for Camzyos (mavacamten) as a potential treatment for ...
From next-generation medications to groundbreaking gene therapies and nonsurgical procedures, explore the pipeline of treatments currently being tested for oHCM.
You're a good cat dad, but even good cat dads get things wrong sometimes. For instance, there's one serious condition that ...
European Launch Follows Strong U.S. StartSOUTH SAN FRANCISCO, Calif., and ZUG, Switzerland, June 01, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, ...
GlobalData on MSN
BMS secures FDA acceptance for Camzyos sNDA
The new application was based on results from the Phase III SCOUT-HCM trial.
The 12-lead ECG hasn't changed in a century. The algorithms reading it have. Three CEOs and one educator on whether doctors ...
US FDA accepts for priority review Bristol Myers Squibb’s sNDA for Camzyos to treat adolescents with symptomatic obstructive hypertrophic cardiomyopathy: Princeton, New Jersey T ...
There’s no cure for obstructive hypertrophic cardiomyopathy (oHCM) — treatments focus on symptom management and preventing complications. But the landscape is changing, and more cutting-edge therapies ...
Nineteen years ago, a Cocoa Beach soccer player died on the field. Now, a new law tries to make sure it doesn't happen again ...
Every second counts I am alive today because the people around me knew what to do when I collapsed during a junior varsity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results